<DOC>
	<DOC>NCT02292719</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of ombitasvir/ABT-450/r with sofosbuvir with or without ribavirin in adults with Genotype 2 Chronic Hepatitis C Virus (HCV)infection or Genotype 3 HCV infection With or Without Cirrhosis.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With and Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>1. Chronic HCV infection prior to study enrollment. 2. Screening laboratory results from the central clinical laboratory indicating HCV genotype 2 or 3 infection only (no mixed genotype). 3. Absence OR presence of cirrhosis. 4. If cirrhotic, need to have compensated cirrhosis and absence of hepatocellular carcinoma (HCC) 1. Positive screen for hepatitis B surface antigen or antihuman immunodeficiency virus antibody 2. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse. 3. Current enrollment in another clinical study, previous enrolment in this study, or previous use of any investigational or commercially available antiHCV therapy (other than interferon, pegIFN, RBV, and or SOF) including previous exposure to telaprevir, boceprevir, ABT450, or ombitasvir (ABT267). 4. Subjects without cirrhosis: Any current or past clinical evidence of cirrhosis. 5. Abnormal lab tests. 6. Females who are pregnant or plan to become pregnant or breastfeeding, or males whose partners are pregnant or planning to become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Genotype 2</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Genotype 3</keyword>
	<keyword>Non-cirrhotic</keyword>
	<keyword>Cirrhotic</keyword>
</DOC>